Infectious Diseases – News and Features

Peregrine Pharmaceuticals, Inc. announces that it has initiated a randomized Phase II clinical trial in patients with previously untreated stage IV pancreatic cancer.

The partnership will lead to a unique multicenter international study into the effect of gene therapy on Wiskott-Aldrich syndrome, a rare genetic disease.

Wyatt Technology Corporation have announced that its instruments were used in a recent landmark study that transforms the previous scientific understanding of immunity to viral diseases like the common cold, 'winter vomiting' and gastroenteritis.

Interface Biologics Inc. announces the signing of a joint development agreement with BASF Future Business GmbH to collaborate in the development of new polymeric formulations with antimicrobial and anti-thrombogenic properties.

Contur Software joins PRIME, a Research Program funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), as informatics partner to assist in their goal to develop a platform for improved modeling of immune processes.

Dynavax Technologies Corporation has reported safety and immunogenicity data from its Phase 1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine.

Astra Biotech GmbH, Berlin, Germany is a new company whose core focus is the development of innovative diagnostics for the identification of an individual’s predisposition to disease.

Researchers have identified a mutation in a gene that could lead to targeted therapies for certain lymphoma patients whose cure rates are currently poor.

Patent claims cover the use of an RNA interference construct to inhibit the level of Hepatitis C virus in cells, tissues and organs.

Horizon Discovery will provide open access to its rAAV GENESIS human gene-editing platform as part of strategy to generate 2500 new in vitro models of cancer, neurodegenerative cardiovascular and infectious diseases.